Partner Linkage Tool for Team Grants: Bringing Biology to Cancer Prevention
The Team Grants: Bringing Biology to Cancer Prevention funding opportunity aims to unite interdisciplinary research teams to advance the biological and mechanistic understanding of cancer etiology, genesis, and risk, linked with host, lifestyle, environmental, social, and other factors, to identify new targets and approaches for cancer prevention, risk reduction, and early detection.
The Partner Linkage Tool aims to facilitate connections between applicants to support the formation of research teams and application development.
To be included in this Partner Linkage Tool, please complete this form. This form can be completed by researchers, knowledge users (e.g., people with lived and living experience, practitioners, policy makers), and applicant partners, who are interested in sharing information and/or establishing collaborations for this funding opportunity.
Note that completing this form is voluntary as it is not a requirement of the application process and does not confer any advantages in the evaluation and funding of applications. Furthermore, potential applicants are not required to contact those who have chosen to make their information available through the Partner Linkage Tool.
By completing and submitting this form, you are consenting to having your responses posted, uneditedFootnote *, and in the language of submission (English or French). You may request to have your information edited or removed at any time by sending a request to cihr.icr@uhn.ca. Requests for edits or removal of information will be actioned regularly. The information provided will be shared publicly in the table below and updated regularly.
Should you have any questions regarding this form or the tool, please email cihr.icr@uhn.ca.
Notice
The information is provided in the language in which it was submitted by the respondent.
| Contact Information | Stakeholder Category | Funding Pool of Interest | Research Area and Expertise | Additional Information |
|---|---|---|---|---|
|
Paola Marignani |
Researcher |
|
Areas of expertise include single-cell RNAseq analysis in primary tumours and tumours from animal models. We apply computational analysis and machine learning algorithms for identifying unique genes and tumour heterogeneity. Areas of signalling expertise include cancer metabolism, LKB1/AMPK/mTOR signalling networks, HER2 receptor signalling, SMARCA4 signalling, mitochondria metabolism. Animal models include: spontaneous mouse models of HER2+ breast cancer, lung cancer and dementia models. |
|
|
Canadian Partnership Against Cancer |
Applicant partner | As the steward of the Canadian Strategy for Cancer Control (the Strategy), the Canadian Partnership Against Cancer (the Partnership) receives ongoing funding from Health Canada to work with provincial and territorial ministries of health and their cancer programs, health system leaders and clinicians, and people affected by cancer across Canada to implement the Strategy to improve cancer outcomes for all people in Canada. |
The Canadian Partnership Against Cancer's OncoSim is available for projects aimed at achieving the goals of the Canadian Strategy for Cancer Control. The OncoSim microsimulation model projects health and economic outcomes for various cancers, enabling users to create and compare scenarios with results that inform cancer service planning. In-kind support includes:
|
|
|
Providence Therapeutics |
Applicant partner | Providence Therapeutics (PTx) is an mRNA Medicines Platform company operating in the RNA field for 10 years. PTx has developed platforms for mRNA and lipid nanoparticle (LNP) medicines that stimulate immune responses to cancers and infectious diseases. Additionally, PTx is able to manufacture vaccines and therapeutics from personalized to pandemic scale. PTx's preclinical pipeline includes programs in oncology, infectious diseases, and animal health, developed both internally and with academic and industry partners. Furthermore, PTx has collaborations with UHN and OICR for research translation on the PTx platform. | Providence Therapeutics offers a comprehensive mRNA Medicines Platform to interested researchers. PTx is committed to leveraging the potential of mRNA technology for the development of innovative mRNA medicines. PTx invites researchers to utilize its proven mRNA platform and LNP technology to translate their discoveries into clinical applications. | |
|
Health Canada's Food and Nutrition Directorate |
Applicant partner | Ultra-processed foods |
Health Canada is the Federal department responsible for helping Canadians maintain and improve their health. Within Health Canada, the Food and Nutrition Directorate has the mandate to:
The Food and Nutrition Directorate includes the Bureau of Chemical Safety and Bureau of Nutritional Sciences. |
Health Canada is interested in projects that aim to better elucidate potential pathways by which ingredients or other substances in ultra-processed foods may affect biological mechanisms related to cancer risk or development. In-kind support may include:
|
|
Canadian Nuclear Laboratories |
Applicant partner | The Canadian Nuclear Laboratories (CNL) is Canada's premier nuclear science and technology organization, and a world leader in developing nuclear technology for peaceful and innovative applications. Using our unique expertise, we are restoring and protecting the environment, we are advancing clean energy technology, and our medical breakthroughs continue to improve the health of people around the world. CNL's unique Biological Research Facility and irradiation capabilities enable iconic long-term in vivo studies of impact of radiation on health. For 75 years, CNL has been at the forefront of innovation in nuclear medicine, radiopharmaceuticals, and low dose radiation research. |
CNL is interested in projects that aim to prevent cancer due to chronic exposure to low dose ionizing radiation that may happen in the environment, such as radon emission, in the workplace, or during repeated medical procedures. In-kind support may include:
|
- Date modified: